MA40957A - Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies - Google Patents

Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies

Info

Publication number
MA40957A
MA40957A MA040957A MA40957A MA40957A MA 40957 A MA40957 A MA 40957A MA 040957 A MA040957 A MA 040957A MA 40957 A MA40957 A MA 40957A MA 40957 A MA40957 A MA 40957A
Authority
MA
Morocco
Prior art keywords
treat diseases
biosynthesis inhibitors
heparane
sulphate
heparane sulphate
Prior art date
Application number
MA040957A
Other languages
English (en)
Inventor
Shripad Bhagwat
Gregory R Luedtke
Mark Spyvee
Bing Wang
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MA40957A publication Critical patent/MA40957A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA040957A 2014-10-09 2015-10-07 Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies MA40957A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462062036P 2014-10-09 2014-10-09

Publications (1)

Publication Number Publication Date
MA40957A true MA40957A (fr) 2017-09-19

Family

ID=55653801

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040957A MA40957A (fr) 2014-10-09 2015-10-07 Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies

Country Status (16)

Country Link
US (1) US20190151312A1 (fr)
EP (1) EP3204009A4 (fr)
JP (1) JP2017530991A (fr)
KR (1) KR20170072242A (fr)
CN (1) CN107106561A (fr)
AR (1) AR102213A1 (fr)
AU (1) AU2015330846A1 (fr)
BR (1) BR112017006705A2 (fr)
CA (1) CA2963607A1 (fr)
IL (1) IL251497A0 (fr)
MA (1) MA40957A (fr)
MX (1) MX2017004618A (fr)
RU (1) RU2017115305A (fr)
TW (1) TW201629051A (fr)
WO (1) WO2016057834A1 (fr)
ZA (1) ZA201703003B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3348547T3 (da) 2015-09-11 2020-09-14 Sumitomo Dainippon Pharma Co Ltd Benzimidazolderivater som nav 1.7 (calciumkanal, spændingsstyret, type ix, alfa undergruppe (scn9a))-inhibitorer til behandling af smerte, dysuria og multipel sclerose
CA3054587A1 (fr) 2017-03-28 2018-10-04 Basf Se Composes pesticides
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
WO2019000683A1 (fr) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Inhibiteur de protéine kinase associée à rho, composition pharmaceutique contenant celui-ci, son procédé de préparation et ses applications
WO2019001572A1 (fr) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Inhibiteur de protéine kinase associée à rho, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
KR102563325B1 (ko) 2017-06-30 2023-08-03 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Rho-관련 단백질 키나아제 억제제, Rho-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
CN107445899A (zh) * 2017-07-19 2017-12-08 枣庄学院 一种苯并咪唑类化合物及其制备方法
CN111587112B (zh) * 2017-09-01 2023-10-10 卡德门企业有限公司 Rho相关含卷曲螺旋蛋白激酶的抑制剂
WO2019120209A1 (fr) 2017-12-20 2019-06-27 Janssen Pharmaceutica Nv Inhibiteurs spiro exo-aza de l'interaction ménine-mll
CN108997343A (zh) * 2018-04-17 2018-12-14 丁敏 一种治疗小儿热性惊厥的药物组合物的制备方法
CN108794470B (zh) * 2018-07-25 2020-06-26 上海毕得医药科技有限公司 一种6-肼基-1H-吡唑并[3,4-b]吡啶及其下游产品的合成方法
US11053501B2 (en) 2018-11-30 2021-07-06 The Penn State Research Foundation Methods of treating neurodegenerative disease by inhibiting N-deacetylase N-sulfotransferase
JP7386997B2 (ja) * 2019-11-15 2023-11-27 イルドン ファーマシューティカル カンパニー リミテッド Glp-1受容体アゴニストおよびその使用
EP4075980B1 (fr) 2019-12-18 2025-07-23 Stinginn LLC 1,2,4-triazoles substitués et procédés d'utilisation
WO2021127282A1 (fr) * 2019-12-18 2021-06-24 Stinginn Llc 1,2,4-triazoles substitués et procédés d'utilisation
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
AU2024309903A1 (en) 2023-06-28 2026-01-08 Psylo Pty Ltd Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2412273T3 (es) * 2002-11-21 2013-07-10 Novartis Ag Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer.
WO2009066084A1 (fr) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2-morpholinopyrimidines et leur utilisation en tant qu'inhibiteurs de kinase pi3
EP2588473A1 (fr) * 2010-06-30 2013-05-08 Amgen Inc. Composés hétérocycliques contenant de l'azote comme inhibiteurs de pi3k-delta

Also Published As

Publication number Publication date
CA2963607A1 (fr) 2016-04-14
WO2016057834A1 (fr) 2016-04-14
EP3204009A1 (fr) 2017-08-16
MX2017004618A (es) 2017-10-23
AR102213A1 (es) 2017-02-15
AU2015330846A1 (en) 2017-05-18
KR20170072242A (ko) 2017-06-26
EP3204009A4 (fr) 2018-05-23
WO2016057834A9 (fr) 2017-04-13
JP2017530991A (ja) 2017-10-19
CN107106561A (zh) 2017-08-29
US20190151312A1 (en) 2019-05-23
RU2017115305A (ru) 2018-11-14
BR112017006705A2 (pt) 2017-12-26
TW201629051A (zh) 2016-08-16
IL251497A0 (en) 2017-05-29
ZA201703003B (en) 2018-04-25

Similar Documents

Publication Publication Date Title
MA40957A (fr) Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies
IL271085A (en) Bacteria for the treatment of disorders
IL257978A (en) Use of pasteurized acrementia to treat metabolic diseases
IL256216A (en) A transgenic bacterium for the treatment of disorders in which there is a breakdown of a split amino acid chain
ZA201801019B (en) Compounds useful for treating disorders related to kit and pdgfr
IL259164A (en) Compounds and compositions useful for treating disorders related to ntrk
ZA201801881B (en) Compounds and compositions useful for treating disorders related to ntrk
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
IL250085A0 (en) New compounds of proton tyrosine kinase inhibitor
IL255831A (en) Inhibitors of bruton's tyrosine kinase
IL244492A0 (en) Broton tyrosine kinase inhibitors
EP3174874A4 (fr) Sels de berbérine, sels ursodésoxycholiques et des combinaisons, des procédés de préparation et d'application correspondants
EP4282479A3 (fr) Utilisation de pridopidine pour traiter la dépression ou l'anxiété
EP2968801A4 (fr) Procédés pour traiter des maladies respiratoires et formulations pour la mise en oeuvre de ceux-ci
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
HUE062714T2 (hu) SGLT2 inhibitorok kutyafélék anyagcserezavarainak kezelésére
MA56412A (fr) Thérapie par l'arn messager pour le traitement des maladies articulaires
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
IL256206A (en) Mct4 inhibitors for treating disease
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
SG11201608397UA (en) Glyt1 inhibitors for use in the treatment of hematological disorders
IL259153A (en) Use of proteasome inhibitors to treat ocular disorders
EP3204028A4 (fr) Composition synergique pour l'arthrose
EP3384005A4 (fr) Supplémentation en arginine pour améliorer l'efficacité des acétogènes de fermentation gazeuse
PL3289875T3 (pl) Zastosowanie środków do kontroli chorób roślin